NBQX, an AMPA antagonist, reduces glutamate-mediated brain edema.
Glutamate (2.5 mg) was administered after the blood-brain barrier had been opened by a unilateral intracarotid infusion of 5 mg protamine sulfate in rats. Whereas the brain specific gravity, measured 24 h later, did not differ between the injected and non-injected side after protamine alone, glutamate significantly reduced the specific gravity in the right hemisphere indicating brain edema (P less than 0.01). NBQX, a potent AMPA receptor antagonist, significantly reduced the edema (P less than 0.01) and completely inhibited the glutamate mediated increase in albumin content in cerebrospinal fluid (P less than 0.01).
Department of Neurology, Lund University Hospital, Sweden.
I
I
Westergren
B B
BB
Johansson
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001812:Blood-Brain Barrier / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D001929:Brain Edema / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D005971:Glutamates / Q000633:toxicity*; D018698:Glutamic Acid; D006400:Hematocrit; D008297:Male; D010069:Oxadiazoles / Q000378:metabolism; D011479:Protamines / Q000494:pharmacology; D011810:Quinoxalines / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D018091:Receptors, AMPA; D017981:Receptors, Neurotransmitter / Q000037:antagonists & inhibitors* / Q000502:physiology; D012709:Serum Albumin / Q000134:cerebrospinal fluid
D005971:Glutamates; D010069:Oxadiazoles; D011479:Protamines; D011810:Quinoxalines; D018091:Receptors, AMPA; D017981:Receptors, Neurotransmitter; D012709:Serum Albumin; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; D018698:Glutamic Acid